: Evidence for differential effects of selective somatostatin

: Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 2004, 89 (10) : 5181–5188.CrossRefPubMed 20. Rozen S, Skaletsky H: Primer3 on the WWW for general

users and for biologist programmers. selleck chemicals llc Methods Mol Biol 2000, 132: 365–386.PubMed 21. Maggi M, Baldi E, Finetti G, Franceschelli F, Brocchi A, Lanzillotti R, Serio M, Camboni MG, Thiele CJ: Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines. Cancer Res 1994, 54 (1) : 124–133.PubMed 22. Watt HL, Kharmate G, Kumar U: Biology of somatostatin in breast cancer. Mol Cell Endocrinol 2008, 286 (1–2) : 251–261.CrossRefPubMed 23. Blaker M, Schmitz M, Gocht A, Burghardt S, Schulz M, Broring DC, Pace A, Greten H, De Weerth A: Differential expression of somatostatin receptor subtypes

in hepatocellular carcinomas. J Hepatol 2004, 41 (1) : 112–118.CrossRefPubMed 24. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW: Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 2005, 133 (1) : 209–220.CrossRefPubMed 25. Kazmi SM, Mishra RK: Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine (mu) and enkephalin (delta) AMN-107 price binding sites. Biochem Biophys Res Commun mafosfamide 1986, 137 (2) : 813–820.CrossRefPubMed 26. Polastron J, Mur M, Mazarguil H, Puget A, Meunier JC, Jauzac P: SK-N-BE: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors. J Neurochem 1994, 62 (3) : 898–906.CrossRefPubMed 27. Allouche S, Hasbi A, Ferey V, Sola B, Jauzac P, Polastron J: Pharmacological delta1- and delta2-opioid receptor subtypes in the human neuroblastoma cell line SK-N-BE: no evidence for distinct molecular entities. Biochem Pharmacol 2000, 59 (8) : 915–925.CrossRefPubMed 28. Porthe G, Frances B, Verrier B, Cros J, Meunier JC: The kappa-opioid receptor from human placenta: hydrodynamic characteristics and evidence for its association with a G protein.

Life Sci 1988, 43 (6) : 559–567.CrossRefPubMed 29. Jaume M, Laffont S, Chapey E, Blanpied C, Dietrich G: Opioid receptor blockade increases the number of lymphocytes without altering T cell response in see more draining lymph nodes in vivo. J Neuroimmunol 2007, 188 (1–2) : 95–102.CrossRefPubMed 30. Tegeder I, Geisslinger G: Opioids as modulators of cell death and survival – unraveling mechanisms and revealing new indications. Pharmacol Rev 2004, 56 (3) : 351–369.CrossRefPubMed 31. Yin D, Mufson RA, Wang R, Shi Y: Fas-mediated cell death promoted by opioids. Nature 1999, 397 (6716) : 218.CrossRefPubMed 32. Delogu G, Moretti S, Antonucci A, Marandola M, Tellan G, Sale P, Carnevali R, Famularo G: Apoptogenic effect of fentanyl on freshly isolated peripheral blood lymphocytes. J Trauma 2004, 57 (1) : 75–81.

Comments are closed.